Abstract: The present invention relates to the preparation of a novel, stable and fast dissolving sub lingual tablets of Nitroglycerin. The oral dosage form of nitroglycerin of the invention can be administered sublingually to treat episodes of angina (chest pain) or just before activities that may cause episodes of angina in order to prevent angina pectoris. The invention preparation is characterized by low degradation profile, maintenance of potency with minimum vaporization of Active Pharmaceutical Ingredient (API) and no migration of nitroglycerin from one dosage unit to another dosage unit or to container or to container components, resulting in excellent stability and better content uniformity on storage in unit-dose or multi-dose containers.
DESC:Attached ,CLAIMS:Attached
| # | Name | Date |
|---|---|---|
| 1 | 202211065737-STATEMENT OF UNDERTAKING (FORM 3) [16-11-2022(online)].pdf | 2022-11-16 |
| 2 | 202211065737-PROVISIONAL SPECIFICATION [16-11-2022(online)].pdf | 2022-11-16 |
| 3 | 202211065737-FORM 1 [16-11-2022(online)].pdf | 2022-11-16 |
| 4 | 202211065737-Proof of Right [13-12-2022(online)].pdf | 2022-12-13 |
| 5 | 202211065737-FORM-26 [20-12-2022(online)].pdf | 2022-12-20 |
| 6 | 202211065737-Others-231222.pdf | 2022-12-26 |
| 7 | 202211065737-GPA-231222.pdf | 2022-12-26 |
| 8 | 202211065737-Correspondence-231222.pdf | 2022-12-26 |
| 9 | 202211065737-Correspondence-231222-1.pdf | 2022-12-26 |
| 10 | 202211065737-CORRESPONDENCE-OTHERS [16-11-2023(online)].pdf | 2023-11-16 |
| 11 | 202211065737-COMPLETE SPECIFICATION [16-11-2023(online)].pdf | 2023-11-16 |
| 12 | 202211065737-Request Letter-Correspondence [23-02-2024(online)].pdf | 2024-02-23 |
| 13 | 202211065737-Form 1 (Submitted on date of filing) [23-02-2024(online)].pdf | 2024-02-23 |
| 14 | 202211065737-Covering Letter [23-02-2024(online)].pdf | 2024-02-23 |